NK cell is the first-line of defense of the body against tumors, and when they are activated by cytokines such as IL-2 and IFN-γ, their roles in killing tumor cells are significantly increased.[43] Our meta-analysis showed that ginsenoside Rg3 combined with chemotherapy could enhance NK cell activity in NSCLC patients compared with the chemotherapy group. The gene discussed is IFNG; the disease is non-small cell lung carcinoma.